Efficacy and Safety Evaluation According to Plasma Concentration Measurement on Direct Oral Anticoagulation Using Factor-Xa Inhibitors for Non-valvular Atrial Fibrillation on Multicenter Study

Efficacy and Safety Evaluation According to Plasma Concentration Measurement on Direct Oral Anticoagulation Using Factor-Xa Inhibitors for Non-valvular Atrial Fibrillation on Multicenter Study - SETtu DOAC Registry(SET DOAC Registry)

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000036769

Enrollment

3000

Registered

2019-05-17

Start date

2018-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-valvular atrial fibrillation

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Non-valvular atrial fibrillation

Exclusion criteria

Exclusion criteria: Patients judged by the attending physician as inappropriate for this study

Design outcomes

Primary

Measure	Time frame
Bleeding and thrombosis events and blood DOAC concentration from the start of medication to 12 months	—

Secondary

Measure	Time frame
Measurement values of molecular markers and coagulation tests from the start of medication to 12 months	—

Countries

Japan

Contacts

Public ContactMichihiro Suwa

Hokusetsu General Hospital Clinical laboratory division

suwa-mic@hokusetsu-hp.jp072-696-2121

Outcome results